Results 41 to 50 of about 2,693 (166)
Potentiation of imipenem by relebactam for Pseudomonas aeruginosa from bacteraemia and respiratory infections [PDF]
Journal of Antimicrobial Chemotherapy, 2019 Imipenem resistance in Pseudomonas aeruginosa most often entails loss of the 'carbapenem-specific' porin OprD; more rarely it reflects acquired carbapenemases. Loss of OprD only confers resistance to imipenem if AmpC β-lactamase is expressed, and we investigated whether this mechanism was overcome by relebactam, a developmental diazabicyclooctane β ...
Carolyne Horner +9 more
openaire +3 more sources
mSphere, 2021 The growing emergence and spread of carbapenem-resistant pathogens worldwide exacerbate the clinical challenge of treating these infections. Given the importance of carbapenems for the treatment of infections caused by Pseudomonas aeruginosa , this study aimed to investigate the underlying genomic properties of the ...
Mario López-Pérez +4 more
openaire +4 more sources
Journal of Microbiology, Immunology and Infection, 2023 Background: Multi-drug resistant Enterobacterales is a growing health threat. Imipenem/relebactam and meropenem/vaborbactam, are not clinically used in Taiwan and the susceptibility is lack from routine laboratory tests.
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
doaj +1 more source
Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik +44 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley +1 more source
ChemMedChem, Volume 21, Issue 9, 14 May 2026.Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez +4 more
wiley +1 more source
Journal of Clinical Laboratory Analysis, Volume 40, Issue 10, May 2026.The primary mechanism of carbapenem resistance identified in pediatric CRKP‐BSI strains was the production of Class B metalloenzymes. We report, for the first time, an outbreak of bloodstream infections in a neonatal ward caused by the dissemination of NDM‐1‐producing ST25 K. pneumoniae.
Mingming Zhou +8 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 608-617, March 2026.This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka +7 more
wiley +1 more source
Journal of Antimicrobial Chemotherapy, 2021 Abstract Background Imipenem/relebactam is a novel carbapenem/β-lactamase inhibitor combination, developed to act against carbapenemase-producing Enterobacterales (CPE). Objectives To assess the in vitro activity of imipenem ...
Juan Carlos Vázquez-Ucha +40 more
openaire +5 more sources
Journal of Global Antimicrobial ResistanceObjectives: Infections caused by carbapenemase-producing Gram-negative pathogens have become a significant global public health challenge due to limited treatment options.
Kengo Hayashi +6 more
doaj +1 more source